161 related articles for article (PubMed ID: 33661520)
1. Systematic evaluation of the 'efficacy-effectiveness gap' in the treatment of depression with venlafaxine and duloxetine.
Schneider C; Breilmann J; Reuter B; Becker T; Kösters M
Acta Psychiatr Scand; 2021 Aug; 144(2):113-124. PubMed ID: 33661520
[TBL] [Abstract][Full Text] [Related]
2. Differences in the placebo response in duloxetine and venlafaxine trials.
Breilmann J; Furukawa TA; Becker T; Koesters M
Acta Psychiatr Scand; 2018 Jun; 137(6):472-480. PubMed ID: 29603140
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine versus other anti-depressive agents for depression.
Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
[TBL] [Abstract][Full Text] [Related]
4. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons.
Eckert L; Lançon C
BMC Psychiatry; 2006 Jul; 6():30. PubMed ID: 16867188
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant treatment effects and country income: meta-regression analysis of individual participant data from duloxetine trials.
Klein T; Weinmann S; Becker T; Koesters M
Acta Psychiatr Scand; 2021 Sep; 144(3):277-287. PubMed ID: 34139020
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.
Schueler YB; Koesters M; Wieseler B; Grouven U; Kromp M; Kerekes MF; Kreis J; Kaiser T; Becker T; Weinmann S
Acta Psychiatr Scand; 2011 Apr; 123(4):247-65. PubMed ID: 20831742
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
8. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G
JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine.
Maneeton N; Maneeton B; Eurviriyanukul K; Srisurapanont M
Drug Des Devel Ther; 2013; 7():1053-62. PubMed ID: 24101861
[TBL] [Abstract][Full Text] [Related]
10. Antidepressants in the treatment for chronic low back pain: questioning the validity of meta-analyses.
Williamson OD; Sagman D; Bruins RH; Boulay LJ; Schacht A
Pain Pract; 2014 Feb; 14(2):E33-41. PubMed ID: 24460577
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P
Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
Ye W; Zhao Y; Robinson RL; Swindle RW
BMC Psychiatry; 2011 Jan; 11():19. PubMed ID: 21281479
[TBL] [Abstract][Full Text] [Related]
13. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches.
Wohlreich MM; Martinez JM; Mallinckrodt CH; Prakash A; Watkin JG; Fava M
J Clin Psychopharmacol; 2005 Dec; 25(6):552-60. PubMed ID: 16282837
[TBL] [Abstract][Full Text] [Related]
14. Ketamine and other glutamate receptor modulators for depression in adults.
Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis.
Rudroju N; Bansal D; Talakokkula ST; Gudala K; Hota D; Bhansali A; Ghai B
Pain Physician; 2013; 16(6):E705-14. PubMed ID: 24284851
[TBL] [Abstract][Full Text] [Related]
16. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
17. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
Li G; Wang X; Ma D
Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
[TBL] [Abstract][Full Text] [Related]
18. Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice.
Singh P; Singh TG
Indian J Pharmacol; 2015; 47(4):388-93. PubMed ID: 26288470
[TBL] [Abstract][Full Text] [Related]
19. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
